Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2016 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer

NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
21. Dezember 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune

NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
15. Dezember 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
16. November 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
09. November 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity

NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
05. November 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Third Quarter 2015 Financial Results

NEW YORK, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
02. November 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi

NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
07. Oktober 2015 08:01 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers

NEW YORK, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
16. September 2015 14:16 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma

NEW YORK, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
14. September 2015 08:00 ET | Quelle: Lion Biotechnologies, Inc.

Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma

NEW YORK, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...

Nächste Seite